Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients

PURPOSE: Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predicting the occurrence of ICI-induced hepatitis are b...

Descripción completa

Detalles Bibliográficos
Autores principales: Purde, Mette-Triin, Niederer, Rebekka, Wagner, Nikolaus B., Diem, Stefan, Berner, Fiamma, Hasan Ali, Omar, Hillmann, Dorothea, Bergamin, Irina, Joerger, Markus, Risch, Martin, Niederhauser, Christoph, Lenz, Tobias L., Früh, Martin, Risch, Lorenz, Semela, David, Flatz, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881258/
https://www.ncbi.nlm.nih.gov/pubmed/34874490
http://dx.doi.org/10.1007/s00432-021-03870-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881258/
https://www.ncbi.nlm.nih.gov/pubmed/34874490
http://dx.doi.org/10.1007/s00432-021-03870-6

Ejemplares similares